Publication | Closed Access

A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer

Placebo-controlled Phase 2MedicinePharmacologyImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyLung Cancer